Pacira collabs with J&J’s MedTech to expand market reach of ZILRETTA

Pacira BioSciences (PCRX) announced a strategic collaboration with Johnson & Johnson (JNJ) MedTech to significantly expand the market reach of ZILRETTA, leveraging its specialized early intervention sales force to co-promote the treatment to existing and new customers. This agreement is expected to significantly expand access and extend reach across a large portion of the seven million intra-articular knee injections administered to patients annually in the U.S. “This partnership embodies our 5×30 strategy of leveraging innovative, targeted collaborations that drive growth, enhance our commercial presence, and improve the patient journey with safe, effective non-opioid treatments,” said Frank Lee, chief executive officer of Pacira BioSciences. “With its proven long-lasting benefits and distinct mechanism of action, ZILRETTA is uniquely positioned to meet a critical need in osteoarthritis pain management, and we believe this agreement will allow us to reach even more patients across the country,” added Lee.